Analyze Diet
Equine veterinary journal2005; 37(3); 257-262; doi: 10.2746/0425164054530669

Changes to oxfendazole chiral kinetics and anthelmintic efficacy induced by piperonyl butoxide in horses.

Abstract: The study of novel pharmacological strategies to control parasitism in horses is required since many parasite species have developed resistance to anthelmintic drugs. Objective: To evaluate the effects of piperonyl butoxide (PB) (a metabolic inhibitor) on the plasma availability and enantiomeric behaviour of oxfendazole (OFZ) given orally to horses, and to compare the clinical efficacy of OFZ given either alone or co-administered with PB in naturally parasitised horses. Methods: Fifteen naturally parasitised crossbred male ponies were allocated into 3 groups (n = 5) and treated orally as follows: Group I (control) received distilled water as placebo; Group II was dosed with OFZ (10 mg/kg bwt); and Group III was treated with OFZ (10 mg/kg bwt) co-administered with PB (63 mg/kg bwt). Jugular blood samples were obtained over 120 h post treatment. Three weeks after treatments, all experimental horses were subjected to euthanasia. Results: The observed maximum plasma concentration (Cmax) and area under the concentration vs. time curve (AUC) values for OFZ increased 3- and 5-fold, respectively, in the presence of PB. The plasma concentration profiles of fenbendazole (FBZ), a metabolite generated from OFZ, were significantly lower after the treatment with OFZ alone (AUC = 0.8 microg x h/ml) compared to those obtained after the OFZ + PB treatment (AUC = 2.7 microg x h/ml). The enhanced pharmacokinetic profiles correlated with increased anthelmintic efficacy. The combination OFZ + PB showed 100% efficacy against mature nematode parasites. The efficacy against cyathostome L3 larvae increased from 94% (Group II) to 98.7% (Group III). Consistently, the number of L4 larvae recovered from OFZ + PB treated horses (Group III) (n = 146) was significantly lower (P<0.05) than that recovered from Group II (n = 1397). Conclusions: The use of PB as a metabolic inhibitor may be useful to enhance OFZ activity against mature and migrating larvae of different parasite species in horses. Conclusions: Metabolic inhibitors may be used to enhance the activity of benzimidazole anthelmintics and extend the effective lifespan of benzimidazole drugs in the face of increasing resistance.
Publication Date: 2005-05-17 PubMed ID: 15892236DOI: 10.2746/0425164054530669Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
  • Clinical Trial
  • Journal Article
  • Randomized Controlled Trial
  • Research Support
  • Non-U.S. Gov't

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

This research investigates the potential for the metabolic inhibitor piperonyl butoxide (PB) to enhance the efficacy of the anthelmintic drug oxfendazole (OFZ) in horses, against both mature and larval parasites, amidst increasing drug resistance.

Study Design

  • The researchers conducted an experiment on fifteen naturally parasitised crossbred male ponies divided into three groups. The division and treatment were as follows:
    • Group I (control group) was given placebo, i.e., distilled water.
    • Group II was given OFZ (10 mg/kg body weight).
    • Group III was jointly treated with OFZ (as above) and PB (63 mg/kg body weight).
  • Blood samples were collected from all ponies over 120 hours post treatment for analysis.
  • After three weeks of treatments, all experimental horses were euthanized for further examination.

Findings

  • The maximum plasma concentration (Cmax) and the area under the concentration vs time curve (AUC), two parameters used to measure drug bioavailability, for OFZ increased drastically when used with PB. Specifically, Cmax and AUC values for OFZ rose by 3 and 5 times, respectively.
  • Plasma concentration profiles of fenbendazole (FBZ), a metabolite of OFZ, were significantly lower after only OFZ treatment compared to when OFZ and PB were jointly administered.
  • The improved pharmacokinetic profiles led to increased anthelmintic efficacy. The dual combination therapy of OFZ+PB showed a 100% efficacy rate against mature nematode parasites. It also improved efficacy against cyathostome L3 larvae from 94% (Group II) to 98.7% (Group III).
  • The number of L4 larvae recovered from horses treated with OFZ+PB was significantly lesser than those treated with OFZ alone, underscoring the enhanced efficacy of the dual therapy.

Conclusions

  • The use of PB as a metabolic inhibitor has shown promise in enhancing the activity of OFZ against mature and migrating larvae of different parasite species in horses.
  • The findings suggest that metabolic inhibitors could be used to reinforce the effectiveness of benzimidazole anthelmintics (a class of deworming compounds that includes OFZ), thus extending the practical lifespan of these drugs even amidst increasing parasite resistance.

Cite This Article

APA
Sánchez Bruni SF, Fusé LA, Moreno L, Saumell CA, Alvarez LI, Fiel C, McKellar QA, Lanusse CE. (2005). Changes to oxfendazole chiral kinetics and anthelmintic efficacy induced by piperonyl butoxide in horses. Equine Vet J, 37(3), 257-262. https://doi.org/10.2746/0425164054530669

Publication

ISSN: 0425-1644
NlmUniqueID: 0173320
Country: United States
Language: English
Volume: 37
Issue: 3
Pages: 257-262

Researcher Affiliations

Sánchez Bruni, S F
  • Facultad de Ciencias Veterinarias, Universidad Nacional del Centro de la Provincia de Buenos Aires, Campus Universitario, 7000, Tandil.
Fusé, L A
    Moreno, L
      Saumell, C A
        Alvarez, L I
          Fiel, C
            McKellar, Q A
              Lanusse, C E

                MeSH Terms

                • Administration, Oral
                • Animals
                • Anthelmintics / blood
                • Anthelmintics / pharmacokinetics
                • Anthelmintics / therapeutic use
                • Area Under Curve
                • Benzimidazoles / blood
                • Benzimidazoles / pharmacokinetics
                • Benzimidazoles / therapeutic use
                • Drug Resistance
                • Drug Synergism
                • Drug Therapy, Combination
                • Feces / parasitology
                • Horse Diseases / drug therapy
                • Horse Diseases / metabolism
                • Horses
                • Male
                • Parasite Egg Count / veterinary
                • Parasitic Diseases, Animal / drug therapy
                • Parasitic Diseases, Animal / metabolism
                • Pesticide Synergists / pharmacology
                • Pesticide Synergists / therapeutic use
                • Piperonyl Butoxide / pharmacology
                • Piperonyl Butoxide / therapeutic use
                • Random Allocation
                • Treatment Outcome

                Citations

                This article has been cited 5 times.
                1. Bach T, Bae S, D'Cunha R, Winokur P, An G. Development and validation of a simple, fast, and sensitive LC/MS/MS method for the quantification of oxfendazole in human plasma and its application to clinical pharmacokinetic study.. J Pharm Biomed Anal 2019 Jul 15;171:111-117.
                  doi: 10.1016/j.jpba.2019.03.048pubmed: 30981954google scholar: lookup
                2. Ceballos L, Moreno L, Torrado JJ, Lanusse C, Alvarez L. Exploring flubendazole formulations for use in sheep. Pharmacokinetic evaluation of a cyclodextrin-based solution.. BMC Vet Res 2012 May 28;8:71.
                  doi: 10.1186/1746-6148-8-71pubmed: 22640491google scholar: lookup
                3. Devine C, Brennan GP, Lanusse CE, Alvarez LI, Trudgett A, Hoey E, Fairweather I. Erratum to: inhibition of triclabendazole metabolism in vitro by ketoconazole increases disruption to the tegument of a triclabendazole-resistant isolate of Fasciola hepatica.. Parasitol Res 2011 Oct;109(4):1209-23.
                  doi: 10.1007/s00436-011-2554-6pubmed: 21858480google scholar: lookup
                4. Devine C, Brennan GP, Lanusse CE, Alvarez LI, Trudgett A, Hoey E, Fairweather I. Inhibition of triclabendazole metabolism in vitro by ketoconazole increases disruption to the tegument of a triclabendazole-resistant isolate of Fasciola hepatica.. Parasitol Res 2011 Oct;109(4):981-95.
                  doi: 10.1007/s00436-011-2304-9pubmed: 21442257google scholar: lookup
                5. Devine C, Brennan GP, Lanusse CE, Alvarez LI, Trudgett A, Hoey E, Fairweather I. Enhancement of the drug susceptibility of a triclabendazole-resistant isolate of Fasciola hepatica using the metabolic inhibitor ketoconazole.. Parasitol Res 2010 Jul;107(2):337-53.
                  doi: 10.1007/s00436-010-1866-2pubmed: 20512589google scholar: lookup